JP2015521465A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521465A5
JP2015521465A5 JP2015516684A JP2015516684A JP2015521465A5 JP 2015521465 A5 JP2015521465 A5 JP 2015521465A5 JP 2015516684 A JP2015516684 A JP 2015516684A JP 2015516684 A JP2015516684 A JP 2015516684A JP 2015521465 A5 JP2015521465 A5 JP 2015521465A5
Authority
JP
Japan
Prior art keywords
sequence
nucleic acid
acid molecule
seq
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521465A (ja
JP6473416B2 (ja
Filing date
Publication date
Priority claimed from GBGB1210357.8A external-priority patent/GB201210357D0/en
Application filed filed Critical
Publication of JP2015521465A publication Critical patent/JP2015521465A/ja
Publication of JP2015521465A5 publication Critical patent/JP2015521465A5/ja
Application granted granted Critical
Publication of JP6473416B2 publication Critical patent/JP6473416B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516684A 2012-06-12 2013-06-12 第viii因子配列 Expired - Fee Related JP6473416B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1210357.8 2012-06-12
GBGB1210357.8A GB201210357D0 (en) 2012-06-12 2012-06-12 Factor VIII sequences
PCT/GB2013/051551 WO2013186563A2 (en) 2012-06-12 2013-06-12 Factor viii sequences

Publications (3)

Publication Number Publication Date
JP2015521465A JP2015521465A (ja) 2015-07-30
JP2015521465A5 true JP2015521465A5 (https=) 2016-08-04
JP6473416B2 JP6473416B2 (ja) 2019-02-20

Family

ID=46605791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516684A Expired - Fee Related JP6473416B2 (ja) 2012-06-12 2013-06-12 第viii因子配列

Country Status (7)

Country Link
US (6) US9447168B2 (https=)
EP (1) EP2859016B1 (https=)
JP (1) JP6473416B2 (https=)
AU (1) AU2013276247B2 (https=)
ES (1) ES2640586T3 (https=)
GB (1) GB201210357D0 (https=)
WO (1) WO2013186563A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
CN105940013B (zh) 2013-12-09 2020-03-27 桑格摩生物科学股份有限公司 用于治疗血友病的方法和组合物
EP3283126B1 (en) * 2015-04-16 2019-11-06 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
TW202446416A (zh) 2015-09-24 2024-12-01 美商拜奧馬林製藥公司 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
CA3005565A1 (en) * 2015-11-13 2017-05-18 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EA202190827A1 (ru) * 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
IL305149A (en) 2016-07-26 2023-10-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
TW202016314A (zh) 2018-05-09 2020-05-01 美商拜奧馬林製藥公司 治療苯丙酮尿症之方法
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
TW202016298A (zh) 2018-05-14 2020-05-01 美商拜奧馬林製藥公司 Aav 載體於幼年受試者中之穩定表現
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
SG11202108357PA (en) 2019-02-15 2021-08-30 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
BR112021015776A2 (pt) * 2019-06-05 2021-11-09 Bayer Healthcare Llc Edição de gene para hemofilia a com expressão de fator viii melhorada
CN112575034B (zh) * 2019-09-29 2023-04-25 济南赛尔生物科技股份有限公司 一种治疗a型血友病的产品及应用
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
US20230407328A1 (en) 2020-11-02 2023-12-21 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
EP4355768A1 (en) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP2025504404A (ja) 2022-01-14 2025-02-12 アンジャリウム バイオサイエンシズ エージー Viii因子をコードするdna分子の組成物、それを作製する方法、及びその使用方法
WO2024007978A1 (zh) 2022-07-07 2024-01-11 深圳新诺微环生物科技有限公司 一种连接肽、包含连接肽的凝血八因子蛋白或其变体及其用途
WO2024238591A2 (en) 2023-05-15 2024-11-21 Biomarin Pharmaceutical Inc. Methods of treating anti-aav seropositive hemophilia patients
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU5689699A (en) 1998-08-24 2000-03-14 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
US20090148906A1 (en) 1998-09-29 2009-06-11 Shire Human Genetic Therapies, Inc. A Delaware Corporation Optimized messenger rna
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
EE200200538A (et) 2000-03-22 2004-04-15 Octagene Gmbh Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
US7351813B2 (en) 2000-06-20 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Liver-specific gene expression cassettes, and methods of use
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
GB0325379D0 (en) 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
WO2006036502A2 (en) 2004-09-22 2006-04-06 St. Jude Children's Research Hospital Improved expression of factor ix in gene therapy vectors
CN1286981C (zh) 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
WO2007084487A2 (en) 2006-01-13 2007-07-26 Wayne State University Pericytes for use as stem cells
ES2535877T3 (es) 2006-06-19 2015-05-18 Asklepios Biopharmaceutical, Inc. Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
CN103849629B (zh) 2006-06-21 2017-06-09 尤尼克尔Ip股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体
DK2173888T3 (en) 2007-07-26 2016-11-28 Uniqure Ip Bv Baculovirus vectors comprising repeating coding sequences WITH differential preferred codons
WO2009017533A1 (en) 2007-07-27 2009-02-05 Porteon Electric Vehicles, Inc. Modular light vehicle chassis
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第viii因子変異体および使用の方法
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
WO2011139629A2 (en) * 2010-04-26 2011-11-10 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
EP3044231B1 (en) 2013-09-12 2020-08-05 BioMarin Pharmaceutical Inc. Aav vectors comprising a gene encoding factor viii

Similar Documents

Publication Publication Date Title
JP2015521465A5 (https=)
JP2020518268A5 (https=)
JP2013509168A5 (https=)
JP2011101646A5 (https=)
JP2022008542A (ja) 高形質導入効率rAAVベクター、組成物、および使用方法
JP2017532966A5 (https=)
IL308514B1 (en) Aav treatment of huntington's disease
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
JP2022534809A5 (https=)
JP2022530633A5 (https=)
JP2014012022A5 (https=)
JP2017536116A5 (https=)
JP2018534950A5 (https=)
JP2020508685A5 (https=)
JP2018138049A5 (https=)
JP2018520997A5 (https=)
WO2013186563A3 (en) Factor viii sequences
JP2013027391A5 (https=)
FI3889173T3 (fi) Optimoitu tekijä viii:n geeni
FI3313991T3 (fi) Muunnettu tekijä IX sekä koostumukset, menetelmät ja käytöt geeninsiirtoa varten soluihin, elimiin ja kudoksiin
WO2012172277A4 (en) Simian adenovirus and hybrid adenoviral vectors
JP2019533439A5 (https=)
CN108368164A (zh) CpG减少的因子VIII变体、组合物和方法以及用于治疗止血障碍的用途
FI3851537T3 (fi) Hyperbilirubinemian hoito
CN107427557A (zh) 用于包装和表达变体因子viii以治疗血友病的改良表达组件